Why Is Avila Therapeutics’ (AVTX) Revenue Forecast Not Optimistic?

During the last trading session, Avalo Therapeutics shares fell by 1.90% and were trading at $2,0600. The dynamics of stock price growth are still weak; stock continues to fall throughout the month. The price fell from $3,0050 to $2,0600. The company’s market capitalization is $211.31 million, and the average intraday trading volume over the past 10 days was 1.52 million shares, and the average trading volume over the past three months was 618.73 thousand shares. Avalo Therapeutics (AVTX) has received a consensus buy recommendation from analysts. This means that the average rating is 1.50.

AVTX has a sales rating of 0 analysts out of 5 analysts who have reviewed these stocks. The company’s earnings per stock (EPS) for the current quarter is expected to be – US$ 0.18. Statistics show that Avalon Therapeutics is inferior to its competitors in terms of stock price compared to the industry in which it operates. Avalon Therapeutics (VRX) stock has fallen by -19.13% over the past six months, while the growth rate since the beginning of the year is lower than the industry average, -45.61% versus 17.80%. According to forecasts of rating companies, revenue will decrease by -18.80% compared to the previous financial year.